{"id":"silicified-microcrystalline-cellulose","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL4297557","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is not an active pharmaceutical ingredient but rather a structural component used in drug manufacturing. It improves tablet hardness, flow properties, and stability by providing mechanical support and reducing moisture absorption. It is commonly used as a filler and binder in oral solid dosage forms.","oneSentence":"Silicified microcrystalline cellulose is an inert pharmaceutical excipient that acts as a binder and flow agent in tablet formulations.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:37:37.395Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT02938520","phase":"PHASE3","title":"Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2016-10-27","conditions":"HIV Infections","enrollment":631},{"nctId":"NCT07388576","phase":"NA","title":"A Clinical Trial to Investigate the Safety and Efficacy of AP-Brain on Cognitive Function at Varying Dosages in Healthy Younger Adults With Self-reported Attention Problems","status":"NOT_YET_RECRUITING","sponsor":"Rousselot BVBA","startDate":"2026-03","conditions":"Cognition, Cognitive Function","enrollment":120},{"nctId":"NCT07388043","phase":"NA","title":"A Clinical Trial to Investigate the Safety and Efficacy of AP-Brain on Cognitive Function at Varying Dosages in Healthy Middle-aged and Older Adults With Self-reported Memory Problems","status":"NOT_YET_RECRUITING","sponsor":"Rousselot BVBA","startDate":"2026-03","conditions":"Cognition, Cognitive Function","enrollment":120},{"nctId":"NCT02951052","phase":"PHASE3","title":"Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"ViiV Healthcare","startDate":"2016-10-28","conditions":"Infection, Human Immunodeficiency Virus, HIV Infections","enrollment":618},{"nctId":"NCT04264897","phase":"PHASE3","title":"Antecedent Metabolic Health and Metformin Aging Study","status":"COMPLETED","sponsor":"Oklahoma Medical Research Foundation","startDate":"2020-07-29","conditions":"Aging, Insulin Sensitivity, Chronic Disease","enrollment":101},{"nctId":"NCT06595706","phase":"PHASE1","title":"Evaluating the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 in Healthy Adult Participants","status":"COMPLETED","sponsor":"Huge Biopharma Australia Pty Ltd","startDate":"2024-09-28","conditions":"Heathy Participants","enrollment":16},{"nctId":"NCT04514510","phase":"PHASE2","title":"Fixed Dose Flavonoid Isoquercetin on Thrombo-Inflammatory Biomarkers in Subjects With Stable Sickle Cell Disease","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2020-11-02","conditions":"Sickle Cell Disease","enrollment":46},{"nctId":"NCT05249621","phase":"PHASE1","title":"A Randomized Phase 1 of of MZE001 in Healthy Volunteers","status":"COMPLETED","sponsor":"Maze Therapeutics","startDate":"2022-02-07","conditions":"Healthy","enrollment":121},{"nctId":"NCT05381025","phase":"NA","title":"Kavalactones on Sleep and Cortisol in Healthy Special Forces Trainees","status":"COMPLETED","sponsor":"Thorne HealthTech, Inc","startDate":"2022-05-11","conditions":"Sleep","enrollment":15},{"nctId":"NCT01737697","phase":"PHASE3","title":"Safety & Efficacy of Zirconium Silicate in Mild to Moderate Hyperkalemia","status":"COMPLETED","sponsor":"ZS Pharma, Inc.","startDate":"2012-11-30","conditions":"Hyperkalemia","enrollment":754},{"nctId":"NCT01493024","phase":"PHASE2","title":"Safety & Efficacy of Zirconium Silicate in Chronic Kidney Disease or Moderate Kidney Dysfunction With Mild Hyperkalemia","status":"COMPLETED","sponsor":"ZS Pharma, Inc.","startDate":"2011-11-30","conditions":"Hyperkalemia, Chronic Kidney Disease, Kidney Dysfunction","enrollment":90},{"nctId":"NCT02921659","phase":"PHASE1, PHASE2","title":"Safety & Efficacy of Nicotinamide Riboside Supplementation for Improving Physiological Function in Middle-Aged and Older Adults","status":"COMPLETED","sponsor":"University of Colorado, Boulder","startDate":"2015-04","conditions":"Aging","enrollment":30},{"nctId":"NCT02333461","phase":"NA","title":"Evaluation of Botanicals for Mechanisms Related to Appetite and Fat Metabolism","status":"COMPLETED","sponsor":"Access Business Group","startDate":"2012-05","conditions":"Overweight, Obesity","enrollment":90},{"nctId":"NCT01866709","phase":"PHASE4","title":"Safety and Efficacy of Sodium Polystyrene Sulfonate in Hyperkalemia","status":"TERMINATED","sponsor":"ZS Pharma, Inc.","startDate":"2013-05","conditions":"Hyperkalemia","enrollment":32},{"nctId":"NCT00780325","phase":"PHASE1","title":"Effects of Dual Cyclooxygenase-2 and Carbonic Anhydrase Inhibition","status":"TERMINATED","sponsor":"University of Pennsylvania","startDate":"2008-10","conditions":"Healthy Volunteers","enrollment":26},{"nctId":"NCT00530452","phase":"PHASE2","title":"Phase II Study of CG100649 for Primary Osteoarthritis in Male Subjects","status":"UNKNOWN","sponsor":"CrystalGenomics, Inc.","startDate":"2007-10","conditions":"Osteoarthritis, Knee, Osteoarthritis, Hip","enrollment":240}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":54,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Placebo"],"phase":"marketed","status":"active","brandName":"Silicified microcrystalline cellulose","genericName":"Silicified microcrystalline cellulose","companyName":"ZS Pharma, Inc.","companyId":"zs-pharma-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Silicified microcrystalline cellulose is a substance studied in clinical trials for various conditions, including aging, insulin sensitivity, and chronic disease, often in combination with metformin. The exact mechanism of action of silicified microcrystalline cellulose is unknown, as indicated by ChEMBL.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}